It has been estimated that up to one-third of patients with diabetes mellitus use some form of complementary and alternative medicine. Momordica charantia (bitter melon) is a popular fruit used for the treatment of diabetes and related conditions amongst the indigenous populations of Asia, South America, India and East Africa. Abundant pre-clinical studies have documented the antidiabetic and hypoglycaemic effects of M. charantia through various postulated mechanisms. However, clinical trial data with human subjects are limited and flawed by poor study design and low statistical power. The present article reviews the clinical data regarding the anti-diabetic potentials of M. charantia and calls for better-designed clinical trials to further elucidate its possible therapeutic effects. 
MATERIALS AND METHODS:
The transdermal films containing the herbal drug component fractionated fromethanolicextract of M. charantia fruits were prepared by using hydroxy propyl methyl cellulose as a polymer. The films were evaluated for folding endurance, thickness, weight variation, drug contents and in vitro diffusion studies and in vivo parameterslike acute and sub-acute antihyperglycemic activity in diabetic rats, biochemicalstudies, skin irritation in rats and stability studies.
RESULT AND DISCUSSION:
The weightof transdermal patches of M. charantia (2 cm(2); 10 mg/patch) and was found to be 0.03 gm.Thickness of patches of M. charantia (2 cm(2); 10 mg/patch) was found to be satisfactory. The percentage release of active constituents from transdermal patches of M.charantia (2 cm(2); 10 mg/patch) was found to be 47.59% in 10% hydroalcoholic phosphate buffer pH 7.4 at the end of 6 h.The transdermal route exhibited negligible skin irritation and in vivo results revealed that the patches successfully decrease the blood glucose level.
CONCLUSION:
From the results, we concluded that the well-known herbal drug M. charantia Linn. have been found to be effective for diabetes through modern pharmaceutical formulation techniques.
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Abstract

BACKGROUND:
Momordica charantia (bitter gourd) is not only a nutritious vegetable but it is also used in traditional medical practices to treat type 2 diabetes mellitus. Experimental studies with animals and humans suggested that the vegetable has a possible role in glycaemic control.
OBJECTIVES:
To assess the effects of mormodica charantia for type 2 diabetes mellitus.
SEARCH METHODS:
Several electronic databases were searched, among these were The Cochrane Library (Issue 1, 2012), MEDLINE, EMBASE, CINAHL, SIGLE and LILACS (all up to February 2012), combined with handsearches. No language restriction was used.
SELECTION CRITERIA:
We included randomised controlled trials (RCTs) that compared momordica charantia with placebo or a control intervention, with or without pharmacological or non-pharmacological interventions.
DATA COLLECTION AND ANALYSIS:
Two authors independently extracted data. Risk of bias of the trials was evaluated using the parameters of randomisation, allocation concealment, blinding, completeness of outcome data, selective reporting and other potential sources of bias. A meta-analysis was not performed given the quality of data and the variability of preparations of momordica charantia used in the interventions (no similar preparation was tested twice).
MAIN RESULTS:
Four randomised controlled trials with up to three months duration and investigating 479 participants met the inclusion criteria. Risk of bias of these trials (only two studies were published as a full peer-reviewed publication) was generally high. Two RCTs compared the effects of preparations from different parts of the momordica charantia plant with placebo on glycaemic control in type 2 diabetes mellitus. There was no statistically significant difference in the glycaemic control with momordica charantia preparations compared to placebo. When momordica charantia was compared to metformin or glibenclamide, there was also no significant change in reliable
